Recent advances in continuous glucose monitoring: Biocompatibility of glucose sensors for implantation in subcutis

Journal of Diabetes Science and Technology

Volumn 1, Issue 5, 2007, Pages 746-752

  Kvist, Peter H ^a   Jensen, Henrik E ^b  

^a LEO PHARMA A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Animal model; Biocompatibility; Continuous glucose monitoring; Glucose sensor; In vivo model; Inflammation; Subcutis

Indexed keywords

EID: 84871337303     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680700100520     Document Type: Article

References (67)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep. 30;329(14):977-86.
2. UK Prospective Diabetes Study (UKPDS). Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 Sep. 12;352(9131):837-53.
3. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec. 22;353(25):2643-53.
4. Sønksen PH, Judd SL, Lowy C. Home monitoring of bloodglucose. Method for improving diabetic control. Lancet. 1978 Apr. 8;1(8067):729-32.
5. Walford S, Gale EA, Allison SP, Tattersall RB. Self-monitoring of blood-glucose. Improvement of diabetic control. Lancet. 1978 Apr. 8;1(8067):732-5.
6. Wickramasinghe Y, Yang Y, Spencer SA. Current problems and potential techniques in in vivo glucose monitoring. J Fluoresc. 2004 Sep; 14(5):513-20.
7. Abel PU, Von Woedtke T. Biosensors for in vivo glucose measurement: can we cross the experimental stage. Biosens Bioelectron. 2002 Dec; 17(11-12):1059-70.
8. Heinemann L, Koschinsky T. Continuous glucose monitoring: an overview of today's technologies and their clinical applications. Int J Clin Pract Suppl. 2002 Jul; (129): 75-9.
9. Sieg A, Guy RH, Delgado-Charro MB. Noninvasive and minimally invasive methods for transdermal glucose monitoring. Diabetes Technol Ther. 2005 Feb; 7(1):174-97.
10. Pickup J, Rolinski O, Birch D. In vivo glucose sensing for diabetes management: progress towards non-invasive monitoring. Interview by Judy Jones. BMJ. 1999 Nov. 13;319(7220):1289.
11. Wilson GS, Gifford R. Biosensors for real-time in vivo measurements. Biosens Bioelectron. 2005 Jun. 15;20(12):2388-403.
12. Rebrin K, Fischer U, HahnVon Dorsche H, Von Woetke T, Abel P, Brunstein E. Subcutaneous glucose monitoring by means of electrochemical sensors: fiction or reality? J Biomed Eng. 1992 Jan; 14(1):33-40.
13. Fischer U. Continuous in vivo monitoring in diabetes: the subcutaneous glucose concentration. Acta Anaesthesiol Scand Suppl. 1995;104:21-9.
14. Fischer U, Hidde A, Herrmann S, Von Woedtke T, Rebrin K, Abel P. Oxygen tension at the subcutaneous implantation site of glucose sensors. Biomed Biochim Acta. 1989;48(11-12):965-71.
15. Rebrin K, Steil GM, Van Antwerp WP, Mastrototaro JJ. Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. Am J Physiol. 1999 Sep; 277(3 Pt 1):E561-71.
16. Cote GL, Lec RM, Pishko MV. Emerging biomedical sensing technologies and their applications. IEEE Sens J. 2003;3:251-66.
17. Pickup JC. In vivo glucose monitoring: sense and sensorbility. Diabetes Care. 1993 Feb; 16(2):535-9.
18. Pfeiffer EF. On the way to the automated (blood) glucose regulation in diabetes: the dark past, the grey present and the rosy future. Diabetologia. 1987 Feb; 30(2):51-65.
19. Valdes TI, Moussy F. In vitro and in vivo degradation of glucose oxidase enzyme used for an implantable glucose biosensor. Diabetes Technol Ther. 2000 Autumn; 2(3):367-76.
20. Fischer U, Ertle R, Abel P, Rebrin K, Brunstein E, Hahn-von D, Freyse EJ. Assessment of subcutaneous glucose concentration: validation of the wick technique as a reference for implanted electrochemical sensors in normal and diabetic dogs. Diabetologia. 1987 Dec; 30(12):940-5.
21. Ishizaka T, Sato T, Kato K, Ohba M, Kimotsuki T, Yasuda M. Subcutaneous continuous glucose monitoring and dose adjustment decreases glycosylated hemoglobin in spontaneously diabetic cynomolgus monkeys. Contemp Top Lab Anim Sci. 2003 Sep; 42(5):36-40.
22. Kvist PH, Bielecki M, Gerstenberg M, Rossmeisl C, Jensen HE, Rolin B, Hasselager E. Evaluation of subcutaneously-implanted glucose sensors for continuous glucose measurements in hyperglycemic pigs. In Vivo. 2006 Mar-Apr; 20(2):195-203.
23. Wiedmeyer CE, Johnson PJ, Cohn LA, Meadows RL. Evaluation of a continuous glucose monitoring system for use in dogs, cats, and horses. J Am Vet Med Assoc. 2003 Oct. 1;223(7):987-92.
24. Davison LJ, Slater LA, Herrtage ME, Church DB, Judge S, Ristic JM, Catchpole B. Evaluation of a continuous glucose monitoring system in diabetic dogs. J Small Anim Pract. 2003 Oct; 44(10):435-42.
25. Rebrin K, Steil GM. Can interstitial glucose assessment replace blood glucose measurements? Diabetes Technol Ther. 2000 Autumn; 2(3):461-72.
26. Moatti-Sirat D, Capron F, Poitout V, Reach G, Bindra DS, Zhang Y, Wilson GS, Thevenot DR. Towards continuous glucose monitoring: in vivo evaluation of a miniaturized glucose sensor implanted for several days in rat subcutaneous tissue. Diabetologia. 1992 Mar; 35(3):224-30.
27. Choleau C, Dokladal P, Klein JC, Ward WK, Wilson GS, Reach G. Prevention of hypoglycemia using risk assessment with a continuous glucose monitoring system. Diabetes. 2002 Nov; 51(11):3263-73.
28. Aussedat B, Dupire-Angel M, Gifford R, Klein JC, Wilson GS, Reach G. Interstitial glucose concentration and glycemia: implications for continuous subcutaneous glucose monitoring. Am J Physiol Endocrinol Metab. 2000 Apr; 278(4):E716-28.
29. Jamali R, Ludvigsson J, Mohseni S. Continuous monitoring of the subcutaneous glucose level in freely moving normal and diabetic rats and in humans with type 1 diabetes. Diabetes Technol Ther. 2002;4(3):305-12.
30. Ristic J M E, Herrtage ME, Walti-Lauger SM, Slater LA, Church DB, Davison LJ, Catchpole B. Evaluation of a continuous glucose monitoring system in cats with diabetes mellitus. J Feline Med Surg. 2005 Jun; 7(3):153-62.
31. Cheyne EH, Cavan DA, Kerr D. Performance of a continuous glucose monitoring system during controlled hypoglycaemia in healthy volunteers. Diabetes Technol Ther. 2002;4(5):607-13.
32. Steil GM, Rebrin K, Mastrototaro J, Bernaba B, Saad MF. Determination of plasma glucose during rapid glucose excursions with a subcutaneous glucose sensor. Diabetes Technol Ther. 2003;5(1):27-31.
33. Johnson KW, Mastrototaro JJ, Howey DC, Brunelle RL, Burden-Brady PL, Bryan NA, Andrew CC, Rowe HM, Allen DJ, Noffke BW, et al. In vivo evaluation of an electroenzymatic glucose sensor implanted in subcutaneous tissue. Biosens Bioelectron. 1992;7(10):709-14.
34. Ishikawa M, Schmidtke DW, Raskin P, Quinn CA. Initial evaluation of a 290-microm diameter subcutaneous glucose sensor: glucose monitoring with a biocompatible, flexible-wire, enzyme-based amperometric microsensor in diabetic and nondiabetic humans. J Diabetes Complications. 1998 Nov-Dec; 12(6):295-301.
35. Djakouré-Platonoff C, Radermercker R, Reach G, Slama G, Selam JI. Accuracy of the continuous glucose monitoring system in inpatient and outpatient conditions. Diabetes Metab. 2003 Apr; 29(2 Pt 1):159-62.
36. Boyne MS, Silver DM, Kaplan J, Saudek CD. Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes. 2003 Nov; 52(11):2790-4.
37. Feldman B, Brazg R, Schwartz S, Weinstein R. A continuous glucose sensor based on wired enzyme technology-results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol Ther. 2003;5(5):769-79.
38. Salardi S, Zucchini S, Santoni R, Ragni L, Gualandi S, Cicognani A, Cacciari E. The glucose area under the profiles obtained with continuous glucose monitoring system relationships with HbA (lc) in pediatric type 1 diabetic patients. Diabetes Care. 2002 Oct; 25(10):1840-4.
39. Von Woedtke T, Fischer U, Brunstein E, Rebrin K, Abel P. Implantable glucose sensors: comparison between in vitro and in vivo kinetics. Int J Artif Organs. 1991 Aug; 14(8):473-81.
40. Abel PU, Von Woedtke T. Biosensors for glycaemic control. Sensor Rev. 2001;21(4):297-304.
41. Pickup JC, Hussain F, Evans ND, Sachedina N. In vivo glucose monitoring: the clinical reality and the promise. Biosens Bioelectron. 2005 Apr. 15;20(10):1897-902.
42. Fischer U, Ertle R, Rebrin K, Freyse EJ. Wick technique: reference method for implanted glucose sensors. Artif Organs. 1989 Oct; 13(5):453-7.
43. Pickup JC, Shaw GW, Claremont DJ. In vivo molecular sensing in diabetes mellitus: an implantable glucose sensor with direct electron transfer. Diabetologia. 1989 Mar; 32(3):213-7.
44. Wilkins E, Atanasov P. Glucose monitoring: state of the art and future possibilities. Med Eng Phys. 1996 Jun; 18(4):273-88.
45. Moussy F, Harrison DJ, Rajotte RV. A miniaturized Nafion-based glucose sensor: in vitro and in vivo evaluation in dogs. Int J Artif Organs. 1994 Feb; 17(2):88-94.
46. Claremont DJ, Sambrook IE, Penton C, Pickup JC. Subcutaneous implantation of a ferrocene-mediated glucose sensor in pigs. Diabetologia. 1986 Nov; 29(11):817-21.
47. Wientjes KJ, Vonk P, Vonk-van Klei Y, Schoonen AJ, Kossen NW. Microdialysis of glucose in subcutaneous adipose tissue up to 3 weeks in healthy volunteers. Diabetes Care. 1998 Sep; 21(9):1481-8.
48. Rahagi FN, Goor JB, Makale MT, Gough DA. Factors that confound the tissue glucose response. Diabetes Technology Meeting. Pennsylvania Convention Center, Philadelphia; 2004.
49. Kvist PH, Iburg T, Bielecki M, Gerstenberg M, Buch-Rasmussen T, Hasselager E, Jensen HE. Biocompatibility of electrochemical glucose sensors implanted in subcutis of pigs. Diabetes Technol Ther. 2006 Aug; 8(4):463-75.
50. Tang L, Eaton JW. Fibrin (ogen) mediates acute inflammatory responses to biomaterials. J Exp Med. 1993 Dec. 1;178(6):2147-56.
51. Maitra M, Abbas AK. The Endocrine System. In: Kumar V, Abbas AK, Fausto N, editors. Robbins and Cotran pathologic basis of disease. Philadelphia (PA): Elsevier Saunders; 2005. p. 1189-1205.
52. Wang YX, Robertson JL, Spillman WB, Claus RO. Effects of the chemical structure and the surface properties of polymeric biomaterials on their biocompatibility. Pharm Res. 2004 Aug; 21(8):1362-73.
53. Tang L, Eaton JW. Inflammatory responses to biomaterials. Am J Clin Pathol. 1995 Apr; 103(4):466-71.
54. Gerritsen M, Jansen JA, Kros A, Nolte RJ, Lutterman JA. Performance of subcutaneously implanted glucose sensors: a review. J Invest Surg. 1998 May-Jun; 11(3):163-74.
55. Mang A, Pill J, Gretz N, Kränzlin B, Buck H, Schoemaker M, Petrich W. Biocompatibility of an electrochemical sensor for continuous glucose monitoring in subcutaneous tissue. Diabetes Technol Ther. 2005 Feb; 7(1):163-73.
56. Klueh U, Kreutzer DL. Murine model of implantable glucose sensors: a novel model for glucose sensor development. Diabetes Technol Ther. 2005 Oct; 7(5):727-37.
57. Ertefai S, Gough DA. Physiological preparation for studying the response of subcutaneously implanted glucose and oxygen sensors. J Biomed Eng. 1989 Sep; 11(5):362-8.
58. Fischer U, Rebrin K, Von Woedtke T, Abel P. Clinical usefulness of the glucose concentration in the subcutaneous tissue-properties and pitfalls of electrochemical biosensors. Horm Metab Res. 1994 Nov; 26(11):515-22.
59. Kvist PH, Iburg T, Aalbaek B, Gerstenberg M, Schoier C, Kaastrup P, Buch-Rasmussen T, Hasselager E, Jensen HE. Biocompatibility of an enzyme-based, electrochemical glucose sensor for short-term implantation implantation in the subcutis. Diabetes Technol Ther. 2006 Oct; 8(5):546-59.
60. Henninger N, Woderer S, Kloetzer HM, Staib A, Gillen R, Li L, Yu X, Gretz N, Kraenzlin B, Pill J. Tissue response to subcutaneous implantation of glucose-oxidase-based glucose sensors in rats. Biosens Bioelectron. 2007 Mar. 30.
61. Hickey T, Kreutzer D, Burgess DJ, Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J Biomed Mater Res. 2002 Aug; 61(2):180-7.
62. Bhardwaj U, Sura R, Papadimitrakopoulos F, Burgess DJ. Controlling acute inflammation with fast releasing dexamethasone-PLGA microsphere/PVA hydrogel composites for implantable devices. J Diabetes Sci Technol. 2007 Jan; 1(1):8-17.
63. Patil SD, Papadimitrakopoulos F, Burgess DJ. Dexamethasoneloaded poly (lactic-co-glycolic) acid microspheres/poly (vinyl alcohol) hydrogel composite coatings for inflammation control. Diabetes Technol Ther. 2004 Dec; 6(6):887-97.
64. Gifford R, Batchelor MM, Lee Y, Gokulrangan G, Meyerhoff ME, Wilson GS. Mediation of in vivo glucose sensor inflammatory response via nitric oxide release. J Biomed Mater Res A. 2005 Dec. 15;75(4):755-66.
65. Van Den Beucken JJ, Walboomers XF, Nillesen ST, Vos MR, Sommerdijk NA, Van Kuppevelt TH, Nolte RJ, Jansen JA. In vitro and in vivo effects of deoxyribonucleic acid-based coatings funtionalized with vascular endothelial growth factor. Tissue Eng. 2007 Apr; 13(4):711-20.
66. Wisniewski N, Reichert M. Methods for reducing biosensor membrane biofouling. Colloids Surf B Biointerfaces. 2000 Oct. 1;18(3-4):197-219.
67. Wisniewski N, Moussy F, Reichert WM. Characterization of implantable biosensor membrane biofouling. Fresenius J Anal Chem. 2000 Mar-Apr; 366(6-7):611-21.